Dr. Zhi Peng 彭智
Chief Physician, Associate Professor
Department of Gastrointestinal Medical Oncology, Peking University Cancer Hospital, Beijing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy, targeted therapy, and comprehensive care for gastric, colorectal, esophageal, pancreatic, and hepatobiliary cancers.
Dr. Peng holds a medical doctorate and serves as a doctoral supervisor. After completing postdoctoral training at Peking University in 2014, Dr. Peng joined the Department of Gastrointestinal Medical Oncology at Peking University Cancer Hospital. In 2015, Dr. Peng provided medical aid in Lhasa for one year. Research focuses on molecular classification, translational research, and drug resistance mechanisms in gastric cancer.
Professional roles
- Member, Gastric Cancer Professional Committee, China Anti-Cancer Association
- Member, Tumor Precision Therapy Committee, China Anti-Cancer Association
- Vice Chair, Digestive Tumor Precision Professional Committee, Beijing Cancer Prevention and Control Society
- Editorial Board Member, Electronic Journal of Comprehensive Oncology
Name order: in Chinese the family name comes first (Peng Zhi). Papers usually list the name as Zhi Peng or Peng Z.
Selected publications
126 papers on PubMed matched by name and affiliation; 33 as first or senior author since 2016. Most recent first- or senior-author papers:
- J Clin Oncol, 2026 (first author): First-Line Retlirafusp Alfa Plus Chemotherapy for Human Epidermal Growth Factor Receptor 2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma: A Randomized, Double-Blind, Phase III Study (RELIGHT). PubMed 42784781
- Sci Bull (Beijing), 2026 (senior author): Tumor empowered binary macrophages regulate T cell interferon signaling to mediate immunotherapy resistance in gastric cancer. PubMed 42542421
- Cell Rep Med, 2026 (senior author): Lactobacillus salivarius potentiates gastrointestinal cancer immunotherapy through its metabolite chenodeoxycholic acid. PubMed 42664954
- Gastric Cancer, 2026 (senior author): Correction: Diagnostic discordance and treatment-associated change of PD-L1 and CLDN18.2 in gastric cancer: a real-world analysis of paired biopsy-resection samples. PubMed 42525321
- Nat Med, 2026 (first author): Savolitinib in MET-amplified gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial. PubMed 42225990
- Gastric Cancer, 2026 (senior author): Diagnostic discordance and treatment-associated change of PD-L1 and CLDN18.2 in gastric cancer: a real-world analysis of paired biopsy-resection samples. PubMed 42029794
- J Immunother Cancer, 2026 (senior author): Fecal microbiota transplantation combined with anti-PD-1 therapy in refractory microsatellite-stable gastric cancer: a phase I feasibility and safety study. PubMed 41871875
- BMJ, 2026 (first author): Camrelizumab plus CAPOX with camrelizumab based maintenance versus CAPOX alone as initial treatment for gastric or gastro-oesophageal junction adenocarcinoma: randomised phase 3 trial. PubMed 41819560
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion